News

FDA approves Perjeta

BY Allison Cerra

SOUTH SAN FRANCISCO, Calif. — Genentech has received regulatory approval for a drug designed to treat breast cancer.

Perjeta (pertuzumab) is approved in combination with Herceptin (trastuzumab) and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. With the approval, Genentech has agreed to post-marketing commitments related to the manufacturing process for Perjeta. These include FDA review of data from the next several productions of the medicine.

"[Today’s] approval of Perjeta is an important advance in the treatment of HER2-positive metastatic breast cancer," said Hal Barron, chief medical officer and head of global product development at Genentech. "Perjeta attacks HER2-positive tumors differently than Herceptin. Based on the way the two medicines work together, the combination plus chemotherapy can prolong the time before this aggressive cancer worsens compared to Herceptin and chemotherapy alone. We are very pleased to see our efforts in studying the science of HER2 translate into another personalized medicine."


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Weis set to reopen former Genuardi’s stores this weekend

BY Allison Cerra

SUNBURY, Pa. — Weis Markets has closed on its purchase of three former Genuardi’s stores and is slated to reopen them this weekend.

In advance of these store openings on June 16, located in Conshohocken, Doylestown and East Norristown, Pa., Weis said it will reopen each store’s pharmacy Monday at 12 noon to minimize prescription service disruption.

Weis added that it has hired 218 former Genuardi employees and has added 150 positions, which will allow each store to double the number of cashiers it employs and increase front-end service.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

3M executive shifts to PepsiCo

BY Allison Cerra

PURCHASE, N.Y. — Mauro Porcini has been named chief design officer at PepsiCo, the company announced.

Porcini, who served as chief design officer at 3M, will responsible for infusing design thinking into PepsiCo’s organization and culture by globally managing design with a creative, innovative and consumer-centered approach for PepsiCo’s brands, with a strong focus on its top 12 global brands: Pepsi, Lay’s, Gatorade, Quaker, Tropicana, Lipton, Sierra Mist/7-Up, Doritos, Cheetos, Mountain Dew, Sun and Mirinda.

Porcini will report to PepsiCo global beverage group president, Brad Jakeman, who also is leading PepsiCo’s long-term plan to drive more design-based innovation.

"At PepsiCo we believe that creating powerful consumer experiences and connections through design is a key lever of growth," Jakeman said. "Mauro is equally as passionate about this belief and will lead the creation of a strong, imaginative and dynamic ecosystem around our brands. For the Pepsi trademark specifically, this ecosystem will remind consumers of the brand’s long-standing connection to pop culture and all things ‘now.’"

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?